Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial

Abstract Temozolomide is a well-tolerated alkylating agent, that is able to permeate the blood–brain barrier (BBB), and has additive cytotoxicity when given with radiotherapy (RT). A phase II trial assessing temozolomide 150 mg/m 2 /day, for 5 days every 28 days in primary central nervous system (CNS) lymphoma (PCNSL) patients with negative human immunodeficienct virus (HIV) serology, Eastern Cooperative Oncology Group (ECOG) performance status (PS)